India has seen a major shift in obesity treatment over the past two years with the wider availability of powerful weight loss medicines such as semaglutide and tirzepatide. These drugs have helped many people lose 15–20% of their body weight — results once possible mainly through surgery.
However, experts warn that stopping these medicines often leads to significant weight regain. Obesity is a chronic, relapsing disease, not a failure of willpower. When weight is lost, the body activates biological mechanisms that increase hunger, reduce fullness and slow metabolism, all pushing weight back up. Weight loss drugs suppress appetite and improve satiety only while they are taken, making withdrawal a critical phase.
A large review of 37 studies involving over 9,000 adults found that people regained an average of 0.4 kg per month after stopping weight loss drugs. For newer medicines like semaglutide and tirzepatide, regain was faster — nearly 0.8 kg per month — with body weight returning to pre-treatment levels in about 1.5 to 2 years. Along with weight, benefits such as improved blood sugar, cholesterol and blood pressure also faded within a similar timeframe.
Weight regain was faster after stopping medicines than after ending structured diet and exercise programmes, likely because lasting behavioural changes offer some protection against rebound gain.
Experts say expectations must change. Like diabetes or high blood pressure, obesity often requires long-term treatment. To limit regain, options include using the lowest effective dose long term, gradual dose tapering, intermittent use, or stepping down to milder, less expensive drugs. Physical activity, increased after weight loss, and structured dietary strategies such as higher protein intake and reduced ultra-processed foods are key.
Weight regain should not be seen as personal failure, but as a biological response. The real challenge now is building long-term, affordable obesity care models that combine medication with strong lifestyle support, especially in India.
